Collaborative treatment of late-life depression in primary care: Implementation of the IMPACT program in Germany

Not Applicable

• Conditions: F32; F33; F34.1; Depressive episode; Recurrent depressive disorder; Dysthymia

• Registration Number: DRKS00003589
• Lead Sponsor: niversitätsklinikum Freiburg Klinik für Psychiatrie und Psychotherapie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09-13
• Study Completion: 2015-10-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 248

Inclusion Criteria

• age: = 60

• major depression of moderate severety (PHQ-9 score 10-14)

• willingness and possibility to partake in telephone calls and personal meetings with the care manager on a regular basis

• willingness to take part in three written surveys (questionnaires) and to be contacted by members of the data management team via telephone

• signing of the patient consent form after having been sufficiently informed about the trial (informed consent)

Exclusion Criteria

• alcohol, drug or pharmaceutical abuse

• significant cognitive impairment (e.g., dementia)

• treatment of depression by a clinical specialist (e.g., psychiatrist, psychotherapist) at time of inclusion

• bipolar disorder

• psychotic symptoms/ severe behavioral symptoms

• risk of suicide at time of inclusion

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome variable is the PHQ-9 score (Kroenke et al. 2001) as a measure of change in the depressive symptoms over the course of the trial. The PHQ-9 questionnaire is the 9-item depression module of the Patient Health Questionnaire which has proven to be a valid instrument for the population of older people with depression in international trials.<br> <br>Along the lines of similar trials (Unützer et al. 2002; IJiff et al. 2007; Gensichen et al. 2009), the change of symptoms in terms of a response to treatment is defined as a decrease of symptoms (PHQ-9 score) by 50% or more. Remission is defined as a reduction of the PHQ-9 score to a score of 4 or less.<br><br>The PHQ-9 will be assessed at the involvement of the patient, after 6 months and after 12 months.